^
Association details:
| Biomarker: | ARID1A deletion |
|---|---|
| Cancer: | Colon Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Excerpt:
We treated nude mice bearing ARID1A-deficient and parental MDA-MB-231 breast cancer tumors and ARID1A-depleted and parental HCT116 colon cancer tumors in the opposite flanks with and without oral 0.33 mg/kg BMN673 daily...HCT116 xenograft mice were only treated with BMN673 for 16 days. After 1 week of treatment, a selective antitumor efficacy of BMN673 was observed in ARID1A-depleted HCT116 cells, and this antitumor effect was more marked at treatment day 16.
DOI:
10.1158/2159-8290.CD-14-0849
